Huo Teh-Ia, Lui Wing-Yu, Huang Yi-Hsiang, Chau Gar-Yang, Wu Jaw-Ching, Lee Pui-Ching, Chang Full-Young, Lee Shou-Dong
Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan.
Am J Gastroenterol. 2003 Oct;98(10):2293-8. doi: 10.1111/j.1572-0241.2003.07688.x.
Patients with hepatocellular carcinoma (HCC) frequently have diabetes mellitus (DM) due to coexisting liver cirrhosis. The aim of this study was to assess the long-term impact of DM on the hepatic regenerative ability of HCC patients undergoing surgical resection.
We retrospectively studied 245 HCC patients (210 male; age, 61 +/- 13 yr) with well-preserved liver functions undergoing resection. Forty (16%) of them were diabetic and were controlled with hypoglycemic agents. The Child-Pugh scoring system was used to evaluate the postoperative liver regeneration ability. The endpoint was the occurrence of hepatic decompensation, defined as a sustained increase in the Child-Pugh score of 2 or more points or the development of tumor recurrence.
Seventy-five patients (31%) developed hepatic decompensation during a follow-up period of 27 +/- 18 months (range, 3-75). DM (p = 0.001), large (>3 cm) tumor size (p = 0.044), and age > 65 yr (p = 0.058) were the factors associated with hepatic decompensation in univariate analysis. Multivariate Cox regression model analysis confirmed that DM (relative risk [RR] = 2.3, 95% CI = 1.4-3.7, p = 0.001) and tumor size > 3 cm (RR = 1.7, 95% CI = 1.1-2.7, p = 0.046) were independent prognostic predictors associated with the occurrence of hepatic decompensation; the respective 3- and 5-yr cumulative rates were 53% and 64% versus 27% and 50% for diabetic and nondiabetic patients, and 24% and 41% versus 38% and 60% for patients with small (< or =3 cm) versus large (>3 cm) tumors.
HCC patients with DM or large tumor size are at a cumulative increased risk for postoperative hepatic decompensation.
肝细胞癌(HCC)患者常因并存肝硬化而患有糖尿病(DM)。本研究旨在评估DM对接受手术切除的HCC患者肝脏再生能力的长期影响。
我们回顾性研究了245例肝功能良好且接受切除手术的HCC患者(210例男性;年龄,61±13岁)。其中40例(16%)为糖尿病患者,通过降糖药物控制病情。采用Child-Pugh评分系统评估术后肝脏再生能力。终点为肝失代偿的发生,定义为Child-Pugh评分持续增加2分或更多分,或出现肿瘤复发。
在27±18个月(范围3 - 75个月)的随访期内,75例患者(31%)发生了肝失代偿。单因素分析中,DM(p = 0.001)、肿瘤大(>3 cm)(p = 0.044)和年龄>65岁(p = 0.058)是与肝失代偿相关的因素。多因素Cox回归模型分析证实,DM(相对风险[RR]=2.3,95%可信区间[CI]=1.4 - 3.7,p = 0.001)和肿瘤大小>3 cm(RR = 1.7,95%CI = 1.1 - 2.7,p = 0.046)是与肝失代偿发生相关的独立预后预测因素;糖尿病患者和非糖尿病患者3年和5年的累积发生率分别为53%和64%,以及27%和50%,小(≤3 cm)肿瘤患者和大(>3 cm)肿瘤患者分别为24%和41%,以及38%和60%。
患有DM或肿瘤较大的HCC患者术后肝失代偿的累积风险增加。